These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36071176)

  • 21. Adapting a conceptual framework to engage diverse stakeholders in genomic/precision medicine research.
    Watson KS; Cohn EG; Fair A; Menon U; Szalacha LA; Carpenter SM; Wilkins CH
    Health Expect; 2022 Aug; 25(4):1478-1485. PubMed ID: 35353945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
    Yeang CH; Beckman RA
    Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic Behavior of p53 Driven by Delay and a Microrna-34a-Mediated Feedback Loop.
    Gao C; Liu H; Yan F
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack Of Diversity In Genomic Databases Is A Barrier To Translating Precision Medicine Research Into Practice.
    Landry LG; Ali N; Williams DR; Rehm HL; Bonham VL
    Health Aff (Millwood); 2018 May; 37(5):780-785. PubMed ID: 29733732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
    Agur Z; Elishmereni M; Foryś U; Kogan Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to escape the cancer attractor: rationale and limitations of multi-target drugs.
    Huang S; Kauffman S
    Semin Cancer Biol; 2013 Aug; 23(4):270-8. PubMed ID: 23792873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.
    El-Chaar NN; Piccolo SR; Boucher KM; Cohen AL; Chang JT; Moos PJ; Bild AH
    Mol Oncol; 2014 Oct; 8(7):1339-54. PubMed ID: 24908424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of senescence in cancer cells by 5'-Aza-2'-deoxycytidine: Bioinformatics and experimental insights to its targets.
    Putri JF; Widodo N; Sakamoto K; Kaul SC; Wadhwa R
    Comput Biol Chem; 2017 Oct; 70():49-55. PubMed ID: 28802167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Personalized Genomics Approach of the Prostate Cancer.
    Iacobas S; Iacobas DA
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prioritizing therapeutic targets using patient-derived xenograft models.
    Lodhia KA; Hadley AM; Haluska P; Scott CL
    Biochim Biophys Acta; 2015 Apr; 1855(2):223-34. PubMed ID: 25783201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The TP53 gene network in a postgenomic era.
    Soussi T
    Hum Mutat; 2014 Jun; 35(6):641-2. PubMed ID: 24753184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomics-Enabled Precision Medicine for Cancer.
    Roos A; Byron SA
    Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation matters in precision medicine: A future to believe in.
    Dey N; Williams C; Leyland-Jones B; De P
    Cancer Treat Rev; 2017 Apr; 55():136-149. PubMed ID: 28371665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioinformatics Approaches for Anti-cancer Drug Discovery.
    Li K; Du Y; Li L; Wei DQ
    Curr Drug Targets; 2020; 21(1):3-17. PubMed ID: 31549592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional precision cancer medicine-moving beyond pure genomics.
    Letai A
    Nat Med; 2017 Sep; 23(9):1028-1035. PubMed ID: 28886003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evidence framework for precision cancer medicine.
    Moscow JA; Fojo T; Schilsky RL
    Nat Rev Clin Oncol; 2018 Mar; 15(3):183-192. PubMed ID: 29255239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine.
    Kyrochristos ID; Roukos DH
    Cancer Treat Rev; 2019 Nov; 80():101894. PubMed ID: 31518831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.